ASMTL Inhibitors

Chemical inhibitors of ASMTL can affect the enzyme's ability to carry out its methylation functions by targeting the availability of its substrates or by altering the cellular environment in which ASMTL operates. Methotrexate, a known inhibitor of dihydrofolate reductase, can lead to a reduced supply of purine nucleotides and subsequently lower the levels of S-adenosylmethionine (SAM), which is required as a methyl donor for the methyltransferase activity of ASMTL. This would result in a functional inhibition of ASMTL's ability to transfer methyl groups. Similarly, both 5-Azacytidine and Decitabine, by integrating into nucleic acids, can inhibit DNA methyltransferases, thereby potentially reducing the methylation status of DNA and affecting the substrate availability for ASMTL. Hydralazine and Procainamide, which also inhibit DNA methyltransferase activity, can further decrease DNA methylation levels, influencing the activity of ASMTL indirectly by modifying the methylation landscape.

Furthermore, chemicals such as RG108, which directly target DNA methyltransferases without incorporating into DNA, can also decrease the methylation status of DNA, thereby impacting ASMTL activity. Disulfiram, by modulating acetylation and methylation status, and Moclobemide, through alterations in monoamine levels, can influence ASMTL activity. Entacapone's inhibition of catechol-O-methyltransferase can change the balance of available methyl groups in the cell, and this has the potential to inhibit ASMTL. Anacardic acid, by inhibiting histone acetyltransferases, can alter the balance between acetylation and methylation, affecting ASMTL's associated pathways. Sinomenine and Parthenolide, by influencing immune signaling and NF-κB activation, respectively, can alter cellular signaling states in a manner that inhibits ASMTL activity.